"Drugs, Investigational" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs which have received FDA approval for human testing but have yet to be approved for commercial marketing. This includes drugs used for treatment while they still are undergoing clinical trials (Treatment IND). The main heading includes drugs under investigation in foreign countries.
| Descriptor ID |
D015507
|
| MeSH Number(s) |
D26.371
|
| Concept/Terms |
Drugs, Investigational- Drugs, Investigational
- Investigational New Drugs
- Drugs, Investigational New
- New Drugs, Investigational
- Investigational Drugs
|
Below are MeSH descriptors whose meaning is more general than "Drugs, Investigational".
Below are MeSH descriptors whose meaning is more specific than "Drugs, Investigational".
This graph shows the total number of publications written about "Drugs, Investigational" by people in this website by year, and whether "Drugs, Investigational" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 1999 | 2 | 1 | 3 |
| 2000 | 0 | 1 | 1 |
| 2002 | 1 | 0 | 1 |
| 2004 | 2 | 0 | 2 |
| 2006 | 1 | 1 | 2 |
| 2007 | 1 | 0 | 1 |
| 2009 | 2 | 0 | 2 |
| 2010 | 2 | 0 | 2 |
| 2011 | 1 | 1 | 2 |
| 2012 | 0 | 1 | 1 |
| 2014 | 2 | 0 | 2 |
| 2015 | 3 | 0 | 3 |
| 2016 | 2 | 0 | 2 |
| 2017 | 4 | 0 | 4 |
| 2018 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
| 2021 | 1 | 0 | 1 |
| 2024 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drugs, Investigational" by people in Profiles.
-
How Aggregate Safety Assessment Planning Supports Investigational New Drug Safety Reporting Decisions. Ther Innov Regul Sci. 2024 Jul; 58(4):579-590.
-
Aggregate IND Safety Reporting for Smaller Companies and Programs. Ther Innov Regul Sci. 2024 03; 58(2):368-379.
-
Interdisciplinary Safety Evaluation for Learning and Decision-Making. Ther Innov Regul Sci. 2021 07; 55(4):705-716.
-
Determining If a Somatic Tumor Mutation Is Targetable and Options for Accessing Targeted Therapies. J Oncol Pract. 2019 11; 15(11):575-583.
-
The Molecular Profiling Lottery: More Accuracy, Less Precision, and No Cost. Clin Cancer Res. 2019 02 15; 25(4):1136-1138.
-
NF-?B in the crosshairs: Rethinking an old riddle. Int J Biochem Cell Biol. 2018 02; 95:108-112.
-
Predicting Successful Phase Advancement and Regulatory Approval in Multiple Myeloma From Phase I Overall Response Rates. JCO Clin Cancer Inform. 2017 11; 1:1-14.
-
Counterpoint: Standard vs Investigational Agents as Upfront Treatment for High-Risk AML. Oncology (Williston Park). 2017 Mar 15; 31(3):190, 192.
-
An Overview of the Fovista and Rinucumab Trials and the Fate of Anti-PDGF Medications. Ophthalmic Surg Lasers Imaging Retina. 2017 02 01; 48(2):100-104.
-
Brincidofovir treatment of acyclovir-resistant disseminated varicella zoster virus infection in an immunocompromised host. Transpl Infect Dis. 2016 Oct; 18(5):785-790.